{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:21:37Z","timestamp":1784132497145,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Diabetes & Endocrinology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/s2213-8587(21)00296-5","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T19:22:26Z","timestamp":1640200946000},"page":"102-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial"],"prefix":"10.1016","volume":"10","author":[{"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dreval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Bondar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulnar","family":"Vagapova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djuro","family":"Macut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia G","family":"Pokramovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E","family":"Molitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Leonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Raverot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Grineva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury E","family":"Poteshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yossi","family":"Gilgun-Sherki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H","family":"Ludlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Patou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asi","family":"Haviv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray B","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke R","family":"Biermasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J","family":"Strasburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S2213-8587(21)00296-5_bib1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/S2213-8587(21)00296-5_bib2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"New Eng J Med"},{"key":"10.1016\/S2213-8587(21)00296-5_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/S2213-8587(21)00296-5_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101309","article-title":"The burden of disease for pituitary patients","volume":"33","author":"Biermasz","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(21)00296-5_bib5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1210\/clinem\/dgaa868","article-title":"Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis","volume":"106","author":"Broersen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(21)00296-5_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/cen.14309","article-title":"Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly","volume":"94","author":"Dichtel","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/S2213-8587(21)00296-5_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.627711","article-title":"Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands","volume":"12","author":"Fleseriu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/S2213-8587(21)00296-5_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/S2213-8587(21)00296-5_bib9","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/jim-2017-000570","article-title":"Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly","volume":"66","author":"Liu","year":"2018","journal-title":"J Investig Med"},{"key":"10.1016\/S2213-8587(21)00296-5_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/S2213-8587(21)00296-5_bib11","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EJE-17-0041","article-title":"Management of endocrine disease: quality of life tools for the management of pituitary disease","volume":"177","author":"Webb","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/S2213-8587(21)00296-5_bib12","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(21)00296-5_bib13","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(21)00296-5_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11102-020-01038-y","article-title":"An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies","volume":"23","author":"Fleseriu","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/S2213-8587(21)00296-5_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/S2213-8587(21)00296-5_bib16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40618-019-01138-y","article-title":"Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study","volume":"43","author":"Colao","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/S2213-8587(21)00296-5_bib17","doi-asserted-by":"crossref","unstructured":"Fleseriu M, Melmed S, Mangal B, Strasburger C, Biermasz N. Longitudinal assessment of response to treatment with oral octreotide capsules in patients with acromegaly: post hoc analysis of a phase 3 trial. European Congress of Endocrinology, Munich, Germany; May 28\u201331, 2016 (poster).","DOI":"10.1530\/endoabs.41.GP151"},{"key":"10.1016\/S2213-8587(21)00296-5_bib18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/S2213-8587(21)00296-5_bib19","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0306-4530(02)00108-7","article-title":"Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change","volume":"28","author":"Pruessner","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/S2213-8587(21)00296-5_bib20","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1530\/EJE-11-0098","article-title":"Clinical and metabolic characteristics of acromegalic patients with high IGF1\/normal GH levels during somatostatin analog treatment","volume":"164","author":"Matta","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/S2213-8587(21)00296-5_bib21","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1210\/jc.2003-032150","article-title":"Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development","volume":"89","author":"Milani","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(21)00296-5_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1365-2265.2000.00876.x","article-title":"Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency","volume":"52","author":"Skjaerbaek","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/S2213-8587(21)00296-5_bib23","first-page":"4099","article-title":"Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg)","volume":"85","author":"Baldelli","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(21)00296-5_bib24","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1210\/jc.2013-2262","article-title":"Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly","volume":"98","author":"Chieffo","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(21)00296-5_bib25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","article-title":"Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study","volume":"18","author":"Sheppard","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/S2213-8587(21)00296-5_bib26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11102-011-0335-y","article-title":"Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly","volume":"15","author":"Tutuncu","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/S2213-8587(21)00296-5_bib27","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/sim.6122","article-title":"A new and improved confidence interval for the Mantel-Haenszel risk difference","volume":"33","author":"Klingenberg","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/S2213-8587(21)00296-5_bib28","author":"Nurminen"},{"key":"10.1016\/S2213-8587(21)00296-5_bib29","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1210\/jc.2001-012012","article-title":"Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size","volume":"87","author":"Bevan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(21)00296-5_bib30","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis","volume":"99","author":"Carmichael","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/S2213-8587(21)00296-5_bib31","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.2165\/00003495-200363220-00014","article-title":"Octreotide long-acting release (LAR): a review of its use in the management of acromegaly","volume":"63","author":"McKeage","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/S2213-8587(21)00296-5_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11102-016-0785-3","article-title":"New medical therapies on the horizon: oral octreotide","volume":"20","author":"Biermasz","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/S2213-8587(21)00296-5_bib33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","article-title":"Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider","volume":"23","author":"Geer","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/S2213-8587(21)00296-5_bib34","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J Clin Endocrinol Metab"}],"updated-by":[{"DOI":"10.1016\/s2213-8587(22)00051-1","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000}}],"container-title":["The Lancet Diabetes & Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213858721002965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213858721002965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:10:48Z","timestamp":1761991848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213858721002965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2213858721002965"],"URL":"https:\/\/doi.org\/10.1016\/s2213-8587(21)00296-5","relation":{},"ISSN":["2213-8587"],"issn-type":[{"value":"2213-8587","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Diabetes & Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S2213-8587(21)00296-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S2213-8587(21)00319-3","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}